Genetics and new treatment modalities for familial Mediterranean fever

Research output: Chapter in Book/Report/Conference proceedingConference contribution

33 Citations (Scopus)

Abstract

Familial Mediterranean fever (FMF) is the most common of a rare group of disorders collectively termed familial hereditary periodic fever syndromes, also known as autoinflammatory syndromes. FMF is clinically characterized by intermittent bouts of fever with peritonitis and abdominal pain, pleuritis, arthritis, or erysipelas-like rashes. Amyloidosis due to chronic inflammation progressing to renal failure is one of the most serious potential complications of this disease. Individuals with FMF have identifiable genetic defects in the Mediterranean fever (MEFV) gene, which codes for the protein pyrin. Pyrin normally blunts neutrophil-mediated inflammation, likely via interleukin-1 (IL-1) downregulation, but is defective in FMF. Potential treatments include colchicine, with case reports of benefits with catecholamine blockade (prazosin), tumor necrosis factor (TNF) antagonism (etanercept, thalidomide), and IL-1 receptor blockade (anakinra).

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages201-208
Number of pages8
Volume1110
DOIs
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1110
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Interleukin 1 Receptor Antagonist Protein
Familial Mediterranean Fever
Thalidomide
Interleukin-1 Receptors
Prazosin
Colchicine
Interleukin-1
Catecholamines
Tumor Necrosis Factor-alpha
Genes
Defects
Hereditary Autoinflammatory Diseases
Proteins
Fever
Erysipelas
Inflammation
Pleurisy
Amyloidosis
Therapeutics
Exanthema

Keywords

  • Amyloidosis
  • Colchicine
  • Familial Mediterranean fever
  • Interferon α
  • Pyrin

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bhat, A., Naguwa, S. M., & Gershwin, M. E. (2007). Genetics and new treatment modalities for familial Mediterranean fever. In Annals of the New York Academy of Sciences (Vol. 1110, pp. 201-208). (Annals of the New York Academy of Sciences; Vol. 1110). https://doi.org/10.1196/annals.1423.022

Genetics and new treatment modalities for familial Mediterranean fever. / Bhat, Anupama; Naguwa, Stanley M; Gershwin, M. Eric.

Annals of the New York Academy of Sciences. Vol. 1110 2007. p. 201-208 (Annals of the New York Academy of Sciences; Vol. 1110).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bhat, A, Naguwa, SM & Gershwin, ME 2007, Genetics and new treatment modalities for familial Mediterranean fever. in Annals of the New York Academy of Sciences. vol. 1110, Annals of the New York Academy of Sciences, vol. 1110, pp. 201-208. https://doi.org/10.1196/annals.1423.022
Bhat A, Naguwa SM, Gershwin ME. Genetics and new treatment modalities for familial Mediterranean fever. In Annals of the New York Academy of Sciences. Vol. 1110. 2007. p. 201-208. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1423.022
Bhat, Anupama ; Naguwa, Stanley M ; Gershwin, M. Eric. / Genetics and new treatment modalities for familial Mediterranean fever. Annals of the New York Academy of Sciences. Vol. 1110 2007. pp. 201-208 (Annals of the New York Academy of Sciences).
@inproceedings{a755845196e648239800b70b17d23389,
title = "Genetics and new treatment modalities for familial Mediterranean fever",
abstract = "Familial Mediterranean fever (FMF) is the most common of a rare group of disorders collectively termed familial hereditary periodic fever syndromes, also known as autoinflammatory syndromes. FMF is clinically characterized by intermittent bouts of fever with peritonitis and abdominal pain, pleuritis, arthritis, or erysipelas-like rashes. Amyloidosis due to chronic inflammation progressing to renal failure is one of the most serious potential complications of this disease. Individuals with FMF have identifiable genetic defects in the Mediterranean fever (MEFV) gene, which codes for the protein pyrin. Pyrin normally blunts neutrophil-mediated inflammation, likely via interleukin-1 (IL-1) downregulation, but is defective in FMF. Potential treatments include colchicine, with case reports of benefits with catecholamine blockade (prazosin), tumor necrosis factor (TNF) antagonism (etanercept, thalidomide), and IL-1 receptor blockade (anakinra).",
keywords = "Amyloidosis, Colchicine, Familial Mediterranean fever, Interferon α, Pyrin",
author = "Anupama Bhat and Naguwa, {Stanley M} and Gershwin, {M. Eric}",
year = "2007",
month = "9",
doi = "10.1196/annals.1423.022",
language = "English (US)",
isbn = "1573317098",
volume = "1110",
series = "Annals of the New York Academy of Sciences",
pages = "201--208",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Genetics and new treatment modalities for familial Mediterranean fever

AU - Bhat, Anupama

AU - Naguwa, Stanley M

AU - Gershwin, M. Eric

PY - 2007/9

Y1 - 2007/9

N2 - Familial Mediterranean fever (FMF) is the most common of a rare group of disorders collectively termed familial hereditary periodic fever syndromes, also known as autoinflammatory syndromes. FMF is clinically characterized by intermittent bouts of fever with peritonitis and abdominal pain, pleuritis, arthritis, or erysipelas-like rashes. Amyloidosis due to chronic inflammation progressing to renal failure is one of the most serious potential complications of this disease. Individuals with FMF have identifiable genetic defects in the Mediterranean fever (MEFV) gene, which codes for the protein pyrin. Pyrin normally blunts neutrophil-mediated inflammation, likely via interleukin-1 (IL-1) downregulation, but is defective in FMF. Potential treatments include colchicine, with case reports of benefits with catecholamine blockade (prazosin), tumor necrosis factor (TNF) antagonism (etanercept, thalidomide), and IL-1 receptor blockade (anakinra).

AB - Familial Mediterranean fever (FMF) is the most common of a rare group of disorders collectively termed familial hereditary periodic fever syndromes, also known as autoinflammatory syndromes. FMF is clinically characterized by intermittent bouts of fever with peritonitis and abdominal pain, pleuritis, arthritis, or erysipelas-like rashes. Amyloidosis due to chronic inflammation progressing to renal failure is one of the most serious potential complications of this disease. Individuals with FMF have identifiable genetic defects in the Mediterranean fever (MEFV) gene, which codes for the protein pyrin. Pyrin normally blunts neutrophil-mediated inflammation, likely via interleukin-1 (IL-1) downregulation, but is defective in FMF. Potential treatments include colchicine, with case reports of benefits with catecholamine blockade (prazosin), tumor necrosis factor (TNF) antagonism (etanercept, thalidomide), and IL-1 receptor blockade (anakinra).

KW - Amyloidosis

KW - Colchicine

KW - Familial Mediterranean fever

KW - Interferon α

KW - Pyrin

UR - http://www.scopus.com/inward/record.url?scp=35748931764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748931764&partnerID=8YFLogxK

U2 - 10.1196/annals.1423.022

DO - 10.1196/annals.1423.022

M3 - Conference contribution

C2 - 17911435

AN - SCOPUS:35748931764

SN - 1573317098

SN - 9781573317092

VL - 1110

T3 - Annals of the New York Academy of Sciences

SP - 201

EP - 208

BT - Annals of the New York Academy of Sciences

ER -